





























- Duchenne muscular dystrophy subjects on daily corticosteroids. *Neuromuscul Disord.* 2013;23(8):618-23.
- [22] Pane M, Mazzone ES, Sormani MP, Messina S, Vita GL, Fanelli L, et al. 6 Minute walk test in Duchenne MD patients with different mutations: 12 month changes. *PLoS One.* 2014;9(1):e83400.
- [23] Pane M, Mazzone ES, Sivo S, Sormani MP, Messina S, A DA, et al. Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes. *PLoS One.* 2014;9(10):e108205.
- [24] Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. *Ann Neurol.* 2016;79(2):257-71.
- [25] Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. *Ann Neurol.* 2013;74(5):637-47.
- [26] McDonald CM, Henricson EK, Abresch RT, Duong T, Joyce NC, Hu F, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: A prospective cohort study. *Lancet.* 2018;391(10119):451-61.
- [27] Brogna C, Coratti G, Pane M, Ricotti V, Messina S, D'Amico A, et al. Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53. *PLoS One.* 2019;14(6):e0218683.
- [28] Goemans N, Mercuri E, Belousova E, Komaki H, Dubrovsky A, McDonald CM, et al. A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy. *Neuromuscular Disorders.* 2018;28(1):4-15.
- [29] McDonald CM, Shieh PB, Abdel-Hamid HZ, Connolly AM, Ciafaloni E, Wagner KR, et al. Open-label evaluation of eteplirsen in patients with Duchenne muscular dystrophy amenable to exon 51 skipping: PROMOV1 trial. *Journal of Neuromuscular Diseases.* 2021(Preprint):1-13.
- [30] ATS statement: Guidelines for the six minute walk test. *American Journal of Respiratory and Critical Care Medicine.* 2002;166(1):111-7.
- [31] Bello L, Morgenroth LP, Gordish-Dressman H, Hoffman EP, McDonald CM, Cirak S, et al. DMD genotypes and loss of ambulation in the CMDRG Duchenne Natural History Study. *Neurology.* 2016;87(10):401-9.
- [32] Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. *American Journal of Respiratory and Critical Care Medicine.* 1990;141(1):119-27.
- [33] Khan N, Eliopoulos H, Han L, Kinane TB, Lowes LP, Mendell JR, et al. Eteplirsen treatment attenuates respiratory decline in ambulatory and non-ambulatory patients with Duchenne muscular dystrophy. *J Neuromuscul Dis.* 2019;6(2):213-25.
- [34] Polgar G, Promadhat V. *Pulmonary function testing in children: Techniques and standards: Saunders Limited;* 1971.
- [35] Goemans N, Signorovitch J, Sajeev G, Yao Z, Gordish-Dressman H, McDonald CM, et al. Suitability of external controls for drug evaluation in Duchenne muscular dystrophy. *Neurology.* 2020; 95(10):e1381-e1391.
- [36] Goemans NM, Tulinius M, van den Hauwe M, Kroksmark AK, Buyse G, Wilson RJ, et al. Long-term efficacy, safety, and pharmacokinetics of drisapersen in Duchenne muscular dystrophy: results from an open-label extension study. *PLoS One.* 2016;11(9):e0161955.
- [37] Schoenfeld D. Partial residuals for the proportional hazards regression model. *Biometrika.* 1982;69(1):239-41.
- [38] Humbertclaude V, Hamroun D, Bezzou K, Bérard C, Boespflug-Tanguy O, Bommelaer C, et al. Motor and respiratory heterogeneity in Duchenne patients: Implication for clinical trials. *European Journal of Paediatric Neurology.* 2012;16(2):149-60.
- [39] Rall S, Grimm T. Survival in Duchenne muscular dystrophy. *Acta Myol.* 2012;31(2):117-20.
- [40] Kinali M, Main M, Eliahoo J, Messina S, Knight RK, Lehovsky J, et al. Predictive factors for the development of scoliosis in Duchenne muscular dystrophy. *European Journal of Paediatric Neurology.* 2007;11(3):160-6.
- [41] Bushby K, Bourke J, Bullock R, Eagle M, Gibson M, Quinby J. The multidisciplinary management of Duchenne muscular dystrophy. *Current Paediatrics.* 2005;15(4):292-300.
- [42] Birnkraus J, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: Respiratory, cardiac, bone health, and orthopaedic management. *The Lancet Neurology.* 2018;17(4):347-61.
- [43] McDonald CM, Henricson EK, Abresch RT, Duong T, Joyce NC, Hu F, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: A prospective cohort study. *The Lancet.* 2018;391(10119):451-61.
- [44] Iff J, Gerrits C, Birk E, Tuttle E, Zheng Y, Henricson E, et al. Delays in progression of Duchenne muscular dystrophy with eteplirsen treatment: attenuation of pulmonary function decline and projected freedom from continuous ventilation. *Neurology.* 2020;94(15 Supplement):1398.
- [45] Wang RT, Barthelemy F, Martin AS, Douine ED, Eskin A, Lucas A, et al. DMD genotype correlations from the Duchenne Registry: Endogenous exon skipping is a factor in prolonged ambulation for individuals with a defined mutation subtype. *Hum Mutat.* 2018;39(9):1193-202.
- [46] McDonald CM, Gordish-Dressman H, Henricson EK, Duong T, Joyce NC, Jhawar S, et al. Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: Long-term natural history with and without glucocorticoids. *Neuromuscular Disorders.* 2018;28(11):897-909.
- [47] McDonald CM, Sajeev G, Yao Z, McDonnell E, Elfiring G, Souza M, et al. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials. *Muscle & Nerve.* 2020;61(1):26-35.
- [48] Goemans N, Signorovitch J, Sajeev G, Fillbrunn M, Wong H, Ward S, et al. P.202A composite prognostic score for time to loss of walking ability in Duchenne muscular dystrophy (DMD). *Neuromus Dis.* 2019;29:S108.